US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

37.53

+0.34000.91%

Post-market: 37.790.2600+0.69%18:24 EST

Volume:476.15K

Turnover:17.84M

Market Cap:335.89M

PE:- -

High:37.70

Open:37.70

Low:37.25

Close:37.19

52wk High:37.70

52wk Low:25.85

Shares:8.95M

Float Shares:8.41M

Volume Ratio:1.04

T/O Rate:5.66%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":37.53,"timestamp":1770411600000,"preClose":37.19,"halted":0,"volume":476146,"hourTrading":{"tag":"盘后","latestPrice":37.79,"preClose":37.53,"latestTime":"18:24 EST","volume":372,"amount":14028.06,"timestamp":1770420288652,"change":0.26,"changeRate":0.006928,"amplitude":0.006928},"delay":0,"changeRate":0.009142242538316844,"floatShares":8410000,"shares":8950000,"eps":0,"marketStatus":"Closed","change":0.34,"latestTime":"02-06 16:00:00 EST","open":37.7,"high":37.7,"low":37.2501,"amount":17839135.097718,"amplitude":0.012097,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":37.19,"sharesOutstanding":9160000,"nav":36.92,"aum":338187200,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":37.4,"preClose":37.19,"latestTime":"09:20 EST","volume":3352,"amount":125515.026584,"timestamp":1770387637633,"change":0.21,"changeRate":0.005647,"amplitude":0.037107},"postHourTrading":{"tag":"盘后","latestPrice":37.79,"preClose":37.53,"latestTime":"18:24 EST","volume":372,"amount":14028.06,"timestamp":1770420288652,"change":0.26,"changeRate":0.006928,"amplitude":0.006928},"volumeRatio":1.039119,"impliedVol":0.0683,"impliedVolPercentile":0.1818},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":8410000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.039119,"shares":8950000,"dividePrice":0,"high":37.7,"amplitude":0.012097,"preClose":37.19,"low":37.2501,"week52Low":25.85,"pbRate":"--","week52High":37.7,"institutionHeld":0,"latestPrice":37.53,"eps":0,"divideRate":0,"volume":476146,"delay":0,"ttmEps":0,"open":37.7,"prevYearClose":34.16,"prevWeekClose":36.48,"prevMonthClose":36.48,"prevQuarterClose":34.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608871324","title":"Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871324","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871324?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123600,"startTime":"0","endTime":"0","summary":"April 10, 2026 Target Action Date for RP1 in Advanced MelanomaWOBURN, Mass., Feb.  03, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3230977/0/en/Replimune-Reports-Fiscal-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"gpt_icon":0},{"id":"2607740100","title":"Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607740100","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607740100?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:01","pubTimestamp":1769634060,"startTime":"0","endTime":"0","summary":"First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3228040/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","LU2362541273.HKD","LU2463526074.USD","NRIX","LU2106854487.HKD","LU0158827781.USD","LU2023250504.SGD","LU0289739343.SGD","LU2362540622.SGD","BK4195","BK4211","LU2240825500.USD","LU2092937221.SGD","LU0124676726.USD","ORR","LU0057025933.USD","BK4533","BK4534","LU1712237335.SGD","LU2023250843.SGD","LU0158827948.USD","LU1721428933.USD","LU1923621640.USD","ASH","LU0689626769.HKD","LU2028103732.USD","LU2362541513.USD","LU1917777945.USD","LU0069063385.USD","BK4585","LU2229751404.USD","LU1623119135.USD","LU1939255532.USD","PFS","LU1430594728.SGD","LU2308191902.HKD","LU0289961442.SGD","LU0347712357.USD","LU2089283258.USD","LU2041044095.USD","LU2298064838.USD","WM","LU1989772923.USD","LU2413666426.HKD","BK4139","LU2089284900.SGD","BK4566","LU0472753341.HKD","LU0511384066.AUD","LU1585245621.USD"],"gpt_icon":0},{"id":"2606919789","title":"Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2606919789","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606919789?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:05","pubTimestamp":1769515500,"startTime":"0","endTime":"0","summary":"-Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in pati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226345/0/en/Cardiff-Oncology-Announces-Positive-Update-from-its-Randomized-Phase-2-Trial-of-Onvansertib-in-First-line-RAS-mutated-mCRC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD6J9T35.USD","BK4195","LU2360107325.USD","LU2357305700.SGD","IE00BZ199S13.USD","ON","PFS","LU1861215975.USD","LU1978683503.SGD","LU1861220033.SGD","ITT","BK4141","IE00BFMHRM44.USD","BK4211","LU1854103824.USD","BK4585","BK4605","LU0054578231.USD","LU1854104046.USD","LU1861214812.USD","LU2298322129.HKD","BK4588","LU1861219969.SGD","LU0124384867.USD","LU1720051108.HKD","LU0053671581.USD","LU1720051017.SGD","ORR","LU0348723411.USD","BK4161","BK4512","LU0724618433.USD","LU1548497426.USD"],"gpt_icon":0},{"id":"2604113780","title":"Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113780","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113780?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914000,"startTime":"0","endTime":"0","summary":"- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and OR","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221679/0/en/Cogent-Biosciences-to-Initiate-New-Drug-Application-NDA-Submission-for-Bezuclastinib-Under-Real-Time-Oncology-Review-RTOR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","LU1670627923.USD","CCOI","BK4532","BK4089","LU1670628061.USD","BK4195","PFS","BK4211"],"gpt_icon":0}],"pageSize":4,"totalPage":37,"pageCount":1,"totalSize":146,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}